Envisagenics Inc Profile last edited on: 9/6/2022
CAGE: 76UL8
UEI: DDJBJ4APF8S3
Business Identifier: Using Artificial Intelligence(AI) and Machine Learning to unlock therapeutic potential of RNA 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
101 Avenue Of The Americas Floor 3
New York, NY 10013
New York, NY 10013
| (516) 847-5485 |
| info@envisagenics.com |
| www.envisagenics.com |
Location: Single
Congr. District: 10
County: Suffolk
Congr. District: 10
County: Suffolk
Public Profile
A bioinformatics firm spun out of Cold Spring Harbor Laboratory, Envisagenics is an Artificial Intelligence-driven biotech structured around discovery of novel RNA splicing variants that cause cancer and other genetic diseases. A woman-owned and minority-led firm - currently resident in JLABS@NYC - the firm's principal technology is the SpliceCore® discovery platform. This involves re-envisioning the human genome with a validated exon-centric approach, combined with machine learning algorithms and high-performance computing.... more likely to discover novel targets than gene-centric discovery tools. Using innovative technology and RNA analysis expertise, Envisagenics accelerates the development of highly specific therapeutics that modulate RNA splicing variants that drive pathogenesis of oncology, neurodegenerative, and metabolic disorders. Having its own internally developed RNA therapeutic programs, the firm partners with biopharmaceutical companies and academic institutions to advance their drug discovery capabilities.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 2 | NIH | $2,075,427 | |
| Project Title: Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data | ||||
| 2019 | 1 | NIH | $301,502 | |
| Project Title: A Software Platform for the Identification of Cell Surface Antigens Using RNA-SEQ Data | ||||
| 2019 | 2 | NIH | $1,850,000 | |
| Project Title: Splicecore: a Cloud-Based Platform to Detect, Quantify and Interpret Alternative Splicing Variation from Next-Generation Sequencing Data. | ||||
Key People / Management
Maria Luisa Pineda -- CEO and Co-Founder
Anson Abraham
Martin Akerman -- CTO, Co-Founder
Gayatrif Arun -- Vice President of Biology
Priyanka Dhingra -- Director of Bioinformatics & Strategic Innovation
Adam Geier -- Back End Software Engineer
Gabi Griffin -- Bioinformatics Scientis
Bradley Harris -- General Counsel and Vice President of Operations
Daniella Kranjac
Robin Munch -- Bioinformatics Analys
Roberto Perales -- Senior Scientis
Roberto Perales -- Senior Scientist
Alan Roemer
Udi Schlessinger -- Director of Data Scienc
Sean Seibel -- Chief Experience Officer
Derrick Stroman -- Operations Manager
Tiffany Tsui -- Director, Program and Alliance Management
Anson Abraham
Martin Akerman -- CTO, Co-Founder
Gayatrif Arun -- Vice President of Biology
Priyanka Dhingra -- Director of Bioinformatics & Strategic Innovation
Adam Geier -- Back End Software Engineer
Gabi Griffin -- Bioinformatics Scientis
Bradley Harris -- General Counsel and Vice President of Operations
Daniella Kranjac
Robin Munch -- Bioinformatics Analys
Roberto Perales -- Senior Scientis
Roberto Perales -- Senior Scientist
Alan Roemer
Udi Schlessinger -- Director of Data Scienc
Sean Seibel -- Chief Experience Officer
Derrick Stroman -- Operations Manager
Tiffany Tsui -- Director, Program and Alliance Management
